Biomedical Applications of Electrospun Nanofibers in the Management of Androgenic Alopecia

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study found that among Chinese males with male androgenic alopecia, combination therapy using topical minoxidil and nano-microneedle-assisted fibroblast growth factor significantly improved hair density, diameter, and follicular unit density over 16 weeks, outperforming individual treatments.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.

This article discusses the autoimmune causes of alopecia areata and reports no new clinical results.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This review discusses the potential of nanotechnology-based formulations for delivering topical minoxidil to improve hair loss treatment outcomes and reports no new clinical results, urging further research into their benefits and safety considerations.

This study reported that polymeric nanofibers containing minoxidil sulphate showed effective encapsulation and stability, with minimal concentration loss over six months, making them potentially ideal for delivering this unstable drug in a more visually appealing and easier-to-apply form.

This review examines the pharmacology, clinical efficacy, and adverse effects of oral finasteride for female pattern hair loss, and discusses potential new treatments like topical finasteride and dutasteride, but reports no new clinical results.

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

This review discusses the potential role of vitamins and minerals in managing non-scarring alopecia but reports no clinical results; the authors advocate for further controlled trials to explore these relationships.

In a study reviewing 291 patients with lichen planopilaris, findings revealed that women were more commonly affected than men, cyclosporine and methotrexate were most effective in achieving remission, and 5-alpha reductase inhibitors and systemic retinoids were particularly beneficial for frontal fibrosing alopecia.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

This review discusses the causes and diagnosis of traction alopecia, emphasizing education for high-risk populations as there is currently no cure, and presents no new clinical findings.

This review discusses unconventional therapies for managing alopecia areata, highlighting antihistamines, cryotherapy, and low-dose naltrexone, but reports no new clinical results and emphasizes the need for further research.

This review summarizes preclinical and clinical information on herbal products for hair loss treatment, highlighting their mechanisms, follicular penetration, and potential side effects, suggesting they may offer alternatives to synthetic drugs with fewer side effects.

In this study, researchers used genetic data from over 52,000 men to identify over 250 genetic loci associated with severe hair loss and developed a predictive algorithm for determining hair loss risk.

Minoxidil response testing helps predict hair growth success.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This review discusses the potential mechanisms and evidence supporting low-level laser therapy for stimulating hair growth in men and women, while noting its safety and effectiveness but needing further study on specific parameters.

This article reviews emerging treatments for androgenetic alopecia, including topical 5-alpha-reductase inhibitors and prostaglandin modulators, but reports no clinical results and calls for further efficacy evidence, especially for PRP.

This study demonstrated the potential of epithelial cell scaffolds fabricated with various materials for effective hair regeneration, highlighting their promising application in tissue engineering for alopecia treatment.

PGD2 stops hair growth and is higher in bald men with AGA.

This study found that increased expression of type II 5α-reductase, androgen receptors, and Hic-5/ARA55 in dermal papilla cells upregulates androgen sensitivity, playing a key role in androgenetic alopecia pathogenesis.

This study concluded that iron deficiency is common among women but not more prevalent in those with female pattern hair loss or chronic telogen effluvium compared to control subjects without hair loss.

This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This study found that while cyproterone acetate, finasteride, and spironolactone had similar short-term effects in treating idiopathic hirsutism, spironolactone provided more lasting benefits one year after treatment.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

This review discusses common hair loss conditions and explores how advancements in hair follicle biology might lead to more effective treatments but reports no new results.

This article describes the potential role of various growth factors and molecules in regulating mammalian hair follicle development but does not present new experimental results.

This study demonstrates that warming hands can restore normal blood flow in patients with systemic sclerosis, making their response to cooling similar to that of healthy controls.